Collateral for a security interest recorded Jul 13, 2026 (Biopharma Credit PLC).
Term ends Dec 3, 2030 · High confidence
20-year base term ended Dec 23, 2023
Held by Esperion Therapeutics, Inc.
Filed Dec 23, 2003 as application 10/743,470 · Granted Feb 26, 2008
Base term plus 711 days of patent term adjustment (USPTO delay)
Today
2003
2030
Clock starts
Dec 23, 2003
Dec 23, 2003
Term ends
Dec 3, 2030
Dec 3, 2030
Granted
Feb 26, 2008
Feb 26, 2008
base term
patent term adjustment
fee events
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
711
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
64
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 711 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 23, 2003, when this application, 10/743,470, was filed | Dec 23, 2023 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +711 days, USPTO patent term adjustment record | Dec 3, 2025 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | +5 years, USPTO 35 U.S.C. 156 certificate | added to Dec 3, 2025: Dec 3, 2030 | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Dec 3, 2030 | High confidence |
Partial family
| Application 08/206,415 | No file history here not computed | not computed |
| Application 08/507,170 | No file history here not computed | not computed |
| US 5,746,223 | Term ended no later than May 2018 | no later than May 2018 |
| US 6,367,479 | Lapsed on the fee record Apr 2010 | Apr 2010 |
| Application 09/060,644 | No file history here not computed | not computed |
| Application 09/071,974 | No file history here not computed | not computed |
| US 6,139,871 | Lapsed on the fee record Oct 2012 | Oct 2012 |
| US 6,312,719 | Lapsed on the fee record Nov 2009 | Nov 2009 |
8 of 64 applications in this family shown, earliest filings first. Partial: 10 of the 64 have no file history here, so a row comes from the patent's own record or names the application alone. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 1, 2004 Reel 15945, frame 158 | Dasseux, Jean-louis Henri; Oniciu, Carmen Daniela | Esperion Therapeutics, Inc. | Assignment of Assignor's Interest |
| Oct 14, 2014 Reel 33946, frame 330 | Esperion Therapeutics, Inc. | Esperion Therapeutics, Inc. | Merger |
| Jun 28, 2019 Reel 49623, frame 629 | Esperion Therapeutics, Inc. | Eiger III S.A. LLC, as Purchaser Agent | Security Interest |
| Jun 27, 2024 Reel 67963, frame 94 | Eiger III S.A. LLC | Esperion Therapeutics, Inc. | Release of Security Interest |
| Dec 13, 2024 Reel 69582, frame 756 | Esperion Therapeutics, Inc. | Glas Americas LLC | Security Interest |
| Jul 13, 2026 Reel 75952, frame 812 | Esperion Therapeutics, Inc.; Resq Pharmaceuticals LLC | Biopharma Credit PLC, as Collateral Agent | Patent Security Agreement |
| Jul 14, 2026 Reel 75267, frame 816 | Glas Americas LLC | Esperion Therapeutics Inc. | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Dec 2030
Term ends Dec 3, 2030. No further fees fall due before then
Note
The 711 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
55
later US patents cite this one
That is top 25% of utility patents granted in 2008 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.